98%
921
2 minutes
20
To provide recommendations for creating and sustaining a treatment-resistant depression (TRD) consultation program at an academic health center. This is a complementary manuscript to Part II, which discusses critical elements of the assessment package for such subspecialized consultations. Participants were a working group of 12 clinicians, researchers, administrators, and patient advocates from the National Network of Depression Centers (NNDC) TRD Task Group. The recommendations are based on expert opinion. TRD consultation programs can offer an individualized treatment roadmap to be implemented by the patient and their providers with the goal of maximizing the likelihood of response or full remission of symptoms. However, there is currently no published work addressing the practical and logistical considerations for establishing such programs. This consensus statement puts forth a set of recommendations that could serve as a basis for future empirical work. Members of the working group provided written descriptions of relevant procedures used at their institutions, which were used during a day-long in-person forum to achieve consensus on recommendations for each major aspect of a TRD consultation program. Subgroups were formed to draft recommendations, and points of disagreement were resolved at subsequent meetings of the full working group. We describe key practical considerations, including systems-level and financial issues; equity and access to TRD care for a diverse patient population; selecting a target population and facilitating the referral process; the product of the consultation; communication between the program, patient, and community providers; and postconsultation care and contact.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4088/JCP.24cs15335 | DOI Listing |
High Alt Med Biol
September 2025
International Commission for Mountain Emergency Medicine (ICAR MEDCOM), Zurich, Switzerland.
McLaughlin, Kyle, Charley Shimanski, Ken Zafren, Ian Jackson, Gerold Biner, Maurizio Folini, Andreas Hermansky, Eric Ridington, Peter Hicks, Giacomo Strapazzon, Marika Falla, Alastair Hopper, Dave Weber, Ryan Jackson, and Hermann Brugger. Helicopter rescue at very high altitude: Recommendations of the International Commission for Mountain Emergency Medicine (ICAR MedCom) 2025. 00:00-00, 2025.
View Article and Find Full Text PDFNat Commun
September 2025
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
With the approval of the antibody-drug conjugate enfortumab vedotin (EV), NECTIN4 has emerged as a bona fide therapeutic target in urothelial carcinoma (UC). Here, we report the development of a NECTIN4-directed chimeric antigen receptor (CAR) T cell, which exhibits reactivity across cells expressing a range of endogenous NECTIN4, with enhanced activity in high expressors. We demonstrate that the PPARγ pathway, critical for luminal differentiation, transcriptionally controls NECTIN4, and that the PPARγ agonist rosiglitazone primes and augments NECTIN4 expression, thereby increasing sensitivity to NECTIN4-CAR T cell-mediated killing.
View Article and Find Full Text PDFAm J Geriatr Psychiatry
August 2025
Department of Psychiatry (MLO, SEC, JZ, KS), Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Neuroimmunology Research Group (KS), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Psychiatric Program of the Netherlands Brain Bank (KS), Ne
Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development.
View Article and Find Full Text PDFJ Immunother Cancer
September 2025
Harold C Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
Background: While highly efficacious for numerous cancers, immune checkpoint inhibitors (ICIs) can cause unpredictable and potentially severe immune-related adverse events (irAEs), underscoring the need to understand irAE biology.
Methods: We used a multidimensional approach incorporating single-cell RNA sequencing, mass cytometry, multiplex cytokine assay, and antinuclear antibody (ANA) profiling to characterize the peripheral immune landscape of patients receiving ICI therapy according to irAE development.
Results: Analysis of 162 patients revealed that individuals who developed clinically significant irAEs exhibited a baseline proinflammatory, autoimmune-like state characterized by a significantly higher abundance of CD57 T and natural killer (NK) T cells, plasmablasts, proliferating and activated CXCR3 lymphocytes, CD8 effector and terminal effector memory T cells, along with reduced NK cells and elevated plasma ANA levels.
J Immunother Cancer
September 2025
Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA
Background: Tumor heterogeneity and antigen escape are mechanisms of resistance to chimeric antigen receptor (CAR)-T cell therapy, especially in solid tumors. Targeting multiple antigens with a unique CAR construct could be a strategy for a better tumor control than monospecific CAR-T cells on heterogeneous models. To overcome tumor heterogeneity, we targeted mesothelin (meso) and Mucin 16 (MUC16), two antigens commonly expressed in solid tumors, using a tandem CAR design.
View Article and Find Full Text PDF